| Code | CSB-RA025270MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Coramitug, targeting transthyretin (TTR), a homotetrameric protein primarily synthesized in the liver and choroid plexus. TTR functions as a carrier protein for thyroxine and retinol-binding protein in plasma and cerebrospinal fluid. Mutations in the TTR gene or age-related destabilization can cause TTR tetramers to dissociate and misfold into amyloid fibrils, leading to transthyretin amyloidosis (ATTR). This progressive, life-threatening condition manifests in two primary forms: hereditary ATTR with polyneuropathy or cardiomyopathy, and wild-type ATTR cardiomyopathy, which predominantly affects elderly populations and results in restrictive cardiomyopathy and heart failure.
Coramitug represents a therapeutic antibody designed to bind misfolded TTR and facilitate the clearance of amyloid deposits through immune-mediated mechanisms. This biosimilar provides researchers with a valuable tool for investigating TTR protein dynamics, amyloid formation pathways, and potential therapeutic interventions for ATTR-related diseases. It supports studies examining protein misfolding mechanisms, antibody-mediated clearance of pathological protein aggregates, and the development of novel treatment strategies for amyloid disorders.
There are currently no reviews for this product.